Clinical Trial Update: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sotorasib and panitumumab versus investigator's choice for colorectal cancer with KRAS p.G12C mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)
• sotorasib (sotorasib)

Snippet

Sponsor: Amgen | Conditions: Colorectal Cancer (CRC) | Phase 3 | Status: COMPLETED